Novartis Shouldn't Rush to Cover Upcoming Patent Expirations -- Market Talk

1507 GMT - Recent clinical-trial setbacks mean Novartis needs to be near-flawless in bringing the rest of its pipeline to the market or look for deals, but the Swiss drugmaker shouldn't rush it, RBC Capital Markets analysts say in a research note. "Shares have pulled back from all-time highs, but we see no urgency to act," the analysts say. The failures of cardiovascular and neuromuscular drugs pelacarsen and del-desiran raise the bar for Novartis's pipeline, given that these were two important candidates to offset sales lost to upcoming patent expirations, they add. RBC starts coverage on the stock with a sector perform recommendation and a target price of 120 Swiss francs. Shares fall 0.3% to 111.44 francs. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

September 09, 2026 11:07 ET (15:07 GMT)